C4 Therapeutics Appoints New Chief Scientific Officer
Company Announcements

C4 Therapeutics Appoints New Chief Scientific Officer

C4 Therapeutics ( (CCCC) ) has shared an update.

C4 Therapeutics has appointed Paige Mahaney, Ph.D., as the new Chief Scientific Officer, succeeding Dr. Stewart Fisher, who will retire but continue as a senior scientific advisor until the end of 2024. Dr. Mahaney, with over 25 years in pharmaceutical and biotech sectors, brings extensive experience in drug discovery and clinical portfolio expansion, which is expected to further advance C4T’s mission in targeted protein degradation science. Her leadership aims to leverage C4T’s innovative TORPEDO® platform, enhancing the development of new therapeutic approaches for challenging diseases.

For detailed information about CCCC stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskC4 Therapeutics Advances in Protein Degradation Therapy
TheFlyC4 Therapeutics files $400M mixed securities shelf
TheFlyC4 Therapeutics files to sell 4.87M shares of common stock for holders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App